Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

ResMed Net Income Climbs 20% to $418 Million in Q1 2026 as Revenue Reaches $1.41 Billion

ResMed Inc. achieved a 20.0% year-over-year increase in net income for the first quarter of fiscal 2026, reaching $418.41 million. The performance was supported by a 6% rise in total revenue and a significant one-time gain from the divestment of subsidiaries.

Mammography, health, mammogram machine, medicine. Stock photo illustrating ResMed's financial results story.
RESMED INC · Photo: AlarconAudiovisual / Pixabay
Results at a glance · $ Million
Metric Q1-26Q1-25
Revenue 1,4151,336
Gross Profit 870.57817.66
Pretax Income 539.15446.79
Net Income 418.41348.54
Diluted EPS 2.922.37
Net Income YoY
+20.0%

Key highlights

  • Total revenue increased to $1,415 million, up from $1,336 million in the prior year period
  • Net income rose to $418.41 million, representing 20.0% growth year-over-year
  • Diluted earnings per share reached $2.92 compared to $2.37 in the first quarter of 2025
  • Gross profit grew to $870.57 million, reflecting sustained demand for core respiratory products
  • Results included a $61.8 million gain recognized from the divestment of subsidiaries

How the Period Went

ResMed's first quarter of fiscal 2026 saw total revenue climb to $1,415 million, a steady increase from the $1,336 million reported in the same period last year. This expansion was primarily fueled by sustained demand for Sleep and Breathing Health products, reflecting broader market growth in medical device availability. The bottom line showed even more pronounced strength, with net income rising 20.0% to $418.41 million, while diluted earnings per share grew to $2.92 from $2.37. This performance underscores a successful start to the fiscal year as the company continues to scale its core respiratory care solutions globally.

Margins and Profitability

Profitability metrics improved during the quarter, with gross profit reaching $870.57 million compared to $817.66 million a year ago. Pretax income saw a sharp jump to $539.15 million from $446.79 million. A major contributor to this bottom-line expansion was a $61.8 million gain recognized from the divestment of certain subsidiaries, which provided a non-recurring boost to the reported net earnings. Despite these exceptional items, ResMed maintained operational efficiency as it managed production costs effectively amidst a complex global supply chain environment for medical electronic components used in its CPAP and ventilation devices.

Business Overview

ResMed Inc. operates as a global leader in the healthcare sector, specifically within the medical instruments and supplies industry. The company specializes in the development, manufacturing, and distribution of medical equipment and cloud-based software applications that diagnose and treat respiratory disorders. Its core business segments are centered on Sleep and Breathing Health, providing continuous positive airway pressure (CPAP) devices, masks, and accessories for patients with sleep apnea and chronic obstructive pulmonary disease (COPD). The firm serves diverse end markets across more than 140 countries, leveraging digital health solutions to improve patient adherence and outcomes.

Financial Context

With a market capitalization of approximately $36.47 billion, ResMed currently trades at a price-to-earnings ratio of 24.24. The stock has experienced a 21.34% price increase over the last quarter, pushing the Relative Strength Index (RSI) to 73.0, which indicates the security is entering overbought territory. Management has reiterated full-year 2027 revenue guidance between $5,750 million and $5,850 million, alongside non-GAAP diluted EPS expected between $12.00 and $12.25. The company's cash flow strategy remains consistent, with a scheduled quarterly cash dividend of $0.66 per share to be paid on December 17, 2026.

RESMED INC share price · last month
Line chart of RESMED INC's share price over the last month, from $239.77 on 19 Oct → $238.19 on 16 Nov; our story on 30 Oct at $252.83.

Down 5.8% since our story on 30 Oct: $252.83 when we broke it → $238.19 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$239.77
20 Oct$245.50
21 Oct$246.20
22 Oct$253.06
23 Oct$252.86
26 Oct$253.20
27 Oct$250.80
28 Oct$250.17
29 Oct$252.83
30 Oct$229.94
2 Nov$232.94
3 Nov$227.08
4 Nov$240.51
5 Nov$239.31
6 Nov$235.30
9 Nov$235.74
10 Nov$234.11
11 Nov$238.53
12 Nov$238.89
13 Nov$239.53
16 Nov$238.19

Industry Landscape

  • The medical device sector continues to benefit from increased global diagnostic rates for sleep-disordered breathing
  • Market demand for digital health and remote patient monitoring tools remains a key growth driver for respiratory care providers
  • Supply chain stability for medical-grade components has improved significantly compared to previous fiscal years
  • Competition remains focused on software integration and patient compliance platforms in the $35 billion global sleep apnea market
  • Peer comparisons show ResMed maintaining a leading position in market share for CPAP hardware and masks
Recent quarters and guidance
DateAnnouncementAmount
29 Oct 2026Q1 FY 2027 net revenueSource: stocktitan.net$1.41 Billion
06 Aug 2026Q4 FY 2026 net revenueSource: morningstar.com$1.46 Billion
30 Apr 2026Q3 FY 2026 net revenueSource: SEC filing$1.43 Billion
29 Jan 2026Q2 FY 2026 net revenueSource: listcorp.com$1.42 Billion
30 Oct 2025Q1 FY 2026 net revenueSource: listcorp.com$1.34 Billion
31 Jul 2025Q4 FY 2025 net revenueSource: globenewswire.com$1.35 Billion
RESMED INC · financial snapshot
Share price$252.83
Market cap$36.5B
Revenue (annual)$5.7B
P/E (TTM)24.2×
1-month price change+13.46%
SectorHealthcareMedical Instruments & Supplies

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by ResMed Inc. announcing its financial results for the first quarter of fiscal year 2026.

Read the filing ↗

Track RESMED INC live

Get the next RESMED INC SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.